Insmed, Inc. (NASDAQ:INSM) Given Average Rating of “Buy” by Brokerages

Shares of Insmed, Inc. (NASDAQ:INSM) have earned an average recommendation of “Buy” from the twenty-four brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $203.4545.

Several analysts recently weighed in on the stock. Bank of America lifted their target price on shares of Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. HC Wainwright lowered their price target on Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Barclays began coverage on Insmed in a report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price objective on the stock. Wedbush set a $203.00 target price on Insmed in a research note on Thursday, December 18th. Finally, Wells Fargo & Company set a $195.00 target price on Insmed in a report on Thursday, December 18th.

Insmed Price Performance

Insmed stock opened at $148.55 on Wednesday. The company’s 50 day simple moving average is $172.50 and its 200-day simple moving average is $161.37. The company has a market capitalization of $31.68 billion, a price-to-earnings ratio of -24.00 and a beta of 1.11. Insmed has a 1 year low of $60.40 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Leo Lee sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the sale, the director directly owned 54,677 shares in the company, valued at approximately $10,711,224.30. The trade was a 57.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 244,857 shares of company stock worth $44,301,247. 3.00% of the stock is owned by company insiders.

Institutional Trading of Insmed

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. grew its position in shares of Insmed by 5.8% in the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after buying an additional 1,112,824 shares during the last quarter. Capital International Investors grew its position in shares of Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after buying an additional 74,994 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Insmed by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after acquiring an additional 539,625 shares during the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.